Related Experiment Videos
Hypertension, genotype and oral contraceptives
Paolo Mulatero1, Stefania Morra di Cella, Franco Veglio
1Department of Medicine and Experimental Oncology, Hypertension Unit, San Vito Hospital, University of Torino, S. San Vito 34 10133 Torino, Italy. paolo.mulatero@libero.it
Pharmacogenomics
|April 23, 2002
Summary
Oral contraceptive-induced hypertension (OCIH) is a blood pressure increase linked to estroprogestin therapy. Recent studies highlight a potential genetic susceptibility influencing OCIH development and pathogenesis.
Area of Science:
- Cardiovascular Medicine
- Pharmacogenomics
- Hypertension Research
Background:
- Oral contraceptive-induced hypertension (OCIH) is a recognized condition where blood pressure rises with estroprogestin therapy.
- Blood pressure typically normalizes within a year of discontinuing oral contraceptives.
- The exact mechanisms driving OCIH remain unclear, prompting investigation into contributing factors.
Purpose of the Study:
- To review the current understanding of OCIH epidemiology.
- To explore the pathogenesis of OCIH.
- To emphasize the role of genetic predisposition in OCIH development based on recent research.
Main Methods:
- Literature review of epidemiological studies on OCIH.
- Analysis of research investigating the pathophysiology of OCIH.
- Synthesis of recent findings on genetic influences in OCIH.
Main Results:
- OCIH is characterized by elevated blood pressure during estroprogestin use.
- Hypertension associated with oral contraceptives resolves after therapy cessation.
- Evidence increasingly points to genetic factors in susceptibility to OCIH.
Conclusions:
- The pathophysiology of OCIH requires further elucidation.
- Genetic susceptibility is a significant area of focus for understanding OCIH.
- Continued research into genetic influences is crucial for managing OCIH.